FINALLY another top #mentalhealth expert on my feed worth following. We need #healing now more than ever! 🙌

Kelly, Bri, and Jordann received the news of Kirsten’s #cancer diagnosis when they were in college. Join us at 6PM PT on Feb. 16 via Zoom as they share how they coped with the loss of their friend, and why they joined forces to co-found b-present. Sign up➡️bit.ly/bpresentjourney

Tonight, we're chatting with AYA #cancer supporters and b-present co-founders Kelly Watson, Jordann Phillips, and Brianna Matias about the challenges they faced as supporters and how they have coped with the loss of a friend. See you at 6 pm PT ➡️ bit.ly/bpresentjourney

Ubuntu is a South African word that means roughly “I am, because of you.” The concept of ubuntu captures both a personal meaning of connection, manifested by warmth and generosity, and a political meaning, represented by inclusion & equity. #ElevateTheConvo

Alto Neuroscience wants to use EEG brain biomarkers to better match the right mental health treatment to a person’s needs. David Levine reports. Alto Neuroscience Amit Etkin Christian Angermayer Tim Kendall CBE Precision for Medicine Mylea Charvat, PhD StartUp Health neo.life/2022/03/precis…

Prescribing drugs for mental illness is a guessing game. A new precision medicine approach from Alto Neuroscience seeks to go beyond clinical assessments & one-size-fits-all pharmacopeias to diagnoses based on advanced imaging & molecular biomarkers. buff.ly/3tHIsOh

This #WorldHealthDay, we’re focused on creating a #HealthierTomorrow by working to bring every person the right treatment for them, right away. Urgent action is needed to address the growing mental health crisis and mental healthcare is a key component of global well-being.

Stunning how high/fast adolescent depression has been increasing. And with little study of treatment options (compared to adults). The New York Times www-nytimes-com.cdn.ampproject.org/c/s/www.nytime…

Our CEO Dr.Amit Etkin will participate on a panel at #BIO2022 (Biotechnology Innovation Organization) tomorrow at 1:45 p.m. PT. He will be joined by other #CNS executives and moderator Allison DeAngelis (STAT) to discuss #DrugDevelopment in the space. Learn more: bio.org/events/bio-int…

Discussion around the recent paper summarizing research on serotonin levels (indexed in different ways) in depression is quite interesting...both for what is mentioned and what is not. The paper: nature.com/articles/s4138… My thoughts in a 🧵

This recent piece by Ned Pagliarulo in BioPharma Dive about the importance of and still very rare role of founder-led biotechs sparked some thoughts from my own experience doing exactly that. Interesting parallels with Jake Becraft's story. A 🧵 below: biopharmadive.com/news/becraft-s…

Our recently published #AltoInMind blog post is part 1 of a 5-part series called The Alto Advantage, where we cover Alto’s guiding principles for pioneering #PrecisionPsychiatry. Read CEO Amit Etkin’s take on how we #RethinkEverything here: bit.ly/3R4IJ7f

In today's PharmaVoice feature, CEO Amit Etkin shares how risking it all to disrupt the status quo is paying off. Read more on our leading #PrecisionPsychiatry drug development approach based on Alto's proprietary platform + novel brain biomarkers here: pharmavoice.com/news/alto-nove…

We are excited to announce a $35M Series B #financing co-led by Lightswitch Capital and Alkeon Capital, including participation from Novartis. We will use these funds to propel our pipeline + platform in #PrecisionPsychiatry forward. Read more: altoneuroscience.com/press-releases…

Part 4 of 5 of The Alto Advantage series focuses on ‘Invested in Impact,’ a value that ties our work together. CFO Nick Smith shares how the Alto team is committed to bringing forward this impact and #innovation for patients. Read more here: altoneuroscience.com/post/the-alto-…

Attending #ACNP2022? Kick off Tuesday morning by attending the “Meet the Expert” session on #PrecisionPsychiatry from 8:30-9:45 a.m. MT, and meet our CEO Amit Etkin to discuss all things #biomarkers in #neuropsychiatry! Learn more and register here: acnp.org/annual-meeting/

#ICYMI, founder & CEO Amit Etkin presented in a Meet the Expert session at #ACNP2022. To learn more and connect with our team, be sure to attend our ACNP presentation of new data Wednesday evening at 5:30 MT during Poster Session III, W105.

Attending J.P. Morgan's 41st Annual Healthcare Conference? Join us on Wednesday, January 11th at 5 p.m. PT for CEO Amit Etkin's presentation highlighting new data and a general corporate update. Read more: altoneuroscience.com/press-releases… #JPM2023

We are honored to be featured in BioSpace's NextGen “Class of 2023” list recognizing this year’s 25 most exciting new companies in #biotech and #pharma across therapeutic areas. In 2023, we can't wait to build on this strong momentum! Read more: biospace.com/article/top-li…

Can EEG and machine learning (ML) predict outcome with psychotherapy? In this new paper in Nature Mental Health, we developed and validated EEG ML biomarkers for predicting outcome with two types of psychotherapy for PTSD. A 🧵 below, and link to the paper: rdcu.be/dacmw